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The exact role of the heparin-releasable hepatic endothelial lipase has remained controversial. It has been 
suggested that it acts in concert with lipoprotein lipase in the step-wise delipidation of triglyceride-rich lipo- 
proteins. On the other hand, there is evidence indicating that high density lipoprotein, is the preferred 
substrate for hepatic lipase. Here, it is shown that a moderate (27%) suppression of hepatic lipase activity 
by estrogen did not impair removal of 3H-labeled very low density lipoproteins (VLDL) triglycerides, sug- 
gesting that this enzyme is not a major regulator of VLDL catabolism under physiological circumstances. 
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1, INTRODUCTION 
Hepatic endothelial lipase (also called hepatic 
triglyceride lipase) is a lipolytic enzyme located in 
the endothelial cells of liver sinusoids [l]. It is 
released into the circulation by intravenous injec- 
tion of heparin and its activity can be quantitated 
in postheparin plasma. It is generally accepted that 
lipoprotein lipase (LPL) is the major regulator of 
the step-wise catabolism of chylomicrons and very 
low density lipoproteins (VLDL), but the 
metabolic role of hepatic lipase has remained con- 
troversial. Recently, several investigators demon- 
strated an impaired removal of triglyceride(TG)- 
rich lipoproteins from the circulation of monkeys 
[2] and rats [3,4] by blocking hepatic lipase (HL) 
activity with specific anti-HL antibodies. They 
suggested that hepatic lipase has a physiological 
role in regulating the conversion of VLDL and in- 
termediate density lipoproteins (IDL) to low den- 
sity lipoproteins (LDL) [2-41. On the other hand, 
evidence has been presented for a major role of 
hepatic lipase in the regulation of plasma high den- 
sity lipoprotein2 (HDLz), and it has been suggested 
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that sex hormone effects on HDL2 are mediated by 
this enzyme [5]. 
Hepatic lipase activity is suppressed by ex- 
ogenous estradiol [5] and its activity even follows 
fluctuations in endogenous estradiol [6]. In order 
to study the suggested regulatory role of hepatic 
lipase in VLDL-TG catabolism we suppressed this 
enzyme by estrogen administration in six 
postmenopausal women and investigated the 
kinetics of VLDL triglycerides labelled en- 
dogenously by injection of [3H]glycerol. The 
removal rate of VLDL triglycerides from plasma 
was not reduced, suggesting that results obtained 
in previous animal studies are not necessarily ap- 
plicable to physiological situations in man. 
2. MATERIALS AND METHODS 
2.1. Subjects 
Six postmenopausal women aged 50-54 years 
volunteered for the study. Except for vasqmotor 
climacteric complaints they were apparently 
healthy. Subject 1 had an elevated serum choles- 
terol level (8.48 mmol/l), whereas the others were 
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normocholesterolemic (range: 4.74-5.80 mmol/l). 
All women had normal serum triglyceride levels 
(range: 0.69- 1.70 mmol/l). Their relative body 
weights ranged between 102 and 158% (mean + 
SD: 128.7 f 21.7%). None of the women was on 
any medication, nor had they received hormonal 
or other treatment known to influence lipid meta- 
bolism during the three months preceding the ini- 
tiation of estrogen. 
2.2. Estrogen treatment 
The VLDL triglyceride turnover studies as well 
as all laboratory examinations were carried out in 
the metabolic ward before starting treatment and 
after three months of oral treatment with estradiol 
valerate (Progynova@, Schering AG, obtained 
from Leiras Ltd, Turku, Finland), 2 mg daily. 
During treatment, all subjects were advised to con- 
tinue their customary way of life including diet, 
drinking habits and exercise. Two subjects never- 
theless lost weight (3.3 and 4.0 kg, see table 2). 
2.3. Determination of serum and VLDL lipids 
The VLDL fraction was isolated in a Sorvall 
OTD-2 ultracentrifuge at solvent density 
1.006 g/ml (18 h) [7]. Cholesterol concentrations 
were determined according to the method of 
RGschlau et al. [8] using a commercial kit 
(no. 187313, Boehringer, Mannheim) and triglycer- 
ide concentrations were analyzed in a Technicon 
Autoanalyzer II (Technicon Instruments, Tarry- 
town, NY, USA) [9]. 
2.4. Determination of VLDL triglyceride turnover 
Turnover studies were carried out using en- 
dogenous labelling of VLDL triglycerides with 
[3H]glycerol [lO,l I]. After i.v. injection of 150 &i 
of [2-3H]glycerol (The Radiochemical Centre, 
Amersham, England, spec. act. 200 mCi/mmol) 
specific activities of VLDL-TG were followed for 
10 h. Fractional rate constants were calculated 
from the monoexponential part of the decay 
curves. Turnover (production) rates (TR) ,umol/h 
expressed per kg of ideal body weight were 
calculated as the product of fractional catabolic 
rate (FCR) and estimated plasma VLDL-TG mass. 
2.5. Determination of postheparin plasma lipase 
activities 
Blood was drawn 5 and 15 min after an i.v. in- 
jection of 100 IU (1 mg) of sodium heparin 
(Leiras, Turku, Finland) per kg body weight. The 
postheparin plasma LPL and HL activities were 
measured by a specific immunochemical method 
[12]. The validity of the method has been discussed 
elsewhere [13,14]. 
3. RESULTS 
3.1. Changes in VLDL- TG kinetic parameters and 
lipase activities 
The effect of the estradiol valerate regimen on 
triglyceride concentrations and postheparin 
plasma lipase activities is shown in table 1. There 
were no significant changes in the average serum or 
VLDL-TG concentrations or LPL activity, but the 
mean HL activity was reduced from 14.0 to 
10.3~mol~h-‘~ml-’ (-27%, p c 0.01). In- 
dividual changes in HL activity are illustrated in 
fig.1 together with the corresponding fractional 
Table 1 
Effect of estradiol valerate (EzV, 2 mg/day) on triglyceride concentrations and 
lipase activities in postheparin plasma in six postmenopausal women 
Triglycerides 
(mmol/l) 
Serum VLDL 
PH-plasma lipase activity 
(umol/h per ml) 
LPL HL 
Pretreatment 1.12 f 0.39 0.69 + 0.28 21.3 + 4.2 14.0 + 4.8 
3 months on EzV 1.32 zk 0.26 0.87 k 0.50 28.0 if: 6.2 10.3 * 4.3 
NS NS NS p < 0.01 
NS, not significant 
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I 2 
VLDL triglycckks in six postmenopausal wo&en 
before (1) and after (2) three months treatmcflt with 
estradiol vaierate, 2 mg/day. (A) Subject I; (a) subject 
2; (A) subject 3; (0) subject 4; (0) subject 5; (v) 
subject 6. 
tions a& kin&c p~F~~&iXS art? SbWfl iFI t&h 2. 
VLDL-TG concentration and turnover (produc- 
tion) rate (TR) increased uring estrogen trea~tment 
in all subjects except in subject 3 who had a reduc- 
tion in both ‘VLDL-TG concentration and TR. 
Significant (3 2%) weight reductions accurrcd in 
two subjects, the greatest being a 4 kg reduction irr 
subject 3 (table 2). The average fractionat cat&bsXic 
rate (FUR) did not change significantly, but there 
was some ~~d~~~d~~~ variation; four subjects ex- 
h%&d aft ~~~~ease mging fTOE% 16 to 56%* one 
@xu%) had no change, and one ~no.6) s~~w~~ a 
Table 2 
Changes in VLDL triglyceride ccmcentratians, turnover rWi% and fractional catabolic razles 
(FCR) in six women after 3 months estrogen treatment (&radiul v&rate, 2 mgfday) 
1. 0.52 +0.18 5.82 +3.12 0.23 ,+ 0.09 14.6 -3.3 
2. 0.46 +O.Il 5.19 + 4.93 0.25 +0,x4 53.1 +0.7 
3, 0.97 - 0.40 11.50 -3.11 0.25 *+ MI6 74.4 -4.0 
4. 0.35 +0.17 7.62 c 3.72 0.48 -f- 0.00 56.0 +0.5 
5. 0.99 + 0.03 9.89 + I.62 0.19 t 0,03 85.5 + 0.0 
6. 0.86 + 0.95 f 3.4@ t&8@ 0.32 -0.09 69.7 - 1.2 
x 0.69 i-O,ff 8_9@ +2_85 Q-29 + O&7 68.9 - I.2 
L I 
r =f: 0,#8, $3 f 0.05 
X = mean vaiue 
Volume 181, number 1 FEBSLETTERS February 1985 
28% decrease. The same subject (no.6) also in- 
creased her VLDL-TG concentration by 110% due 
to development of VLDL-TG overproduction 
(20,2~mol/kg per h) during estrogen therapy 
(fig.1; table 2). 
3.2. Correlations 
The changes in VLDL-TG concentrations cor- 
related positively with those in turnover rates (r = 
0.88, p < 0.05; table 2), but not with the changes 
in LPL or HL activity. The results were essentially 
similar when calculations were repeated using TR 
values expressed as mmol/h per kg body weight, or 
mmol/h. No significant correlations existed bet- 
ween FCR and postheparin plasma LPL or HL 
activities. 
4. DISCUSSION 
Some previous studies have suggested that 
hepatic lipase acts in concert with lipoprotein 
lipase in the catabolism of TG-rich lipoproteins 
along the VLDL - IDL - LDL pathway [2-4). 
Stimulated by these reports we set out to test this 
hypothesis by investigating the turnover kinetics of 
VLDL-TG in the presence and absence of 
estrogen-induced suppression of hepatic lipase. 
The results indicate that suppression of HL activity 
in postheparin plasma was not accompanied by im- 
paired clearance of VLDL-TG from plasma (in 
terms of a diminished FCR). Hence, the in- 
crements in VLDL-TG (table 2) were most likely 
caused by augmentation of VLDL-TG turnover 
(production) rates, as suggested by the positive 
correlation between the changes in VLDL-TG con- 
centrations and turnover rates. 
In calculating FCR we used single-exponential 
analysis of the 8-h decay curve. Thus, the late ‘tail’ 
of the decay curve caused by the slowly turning- 
over compartment postulated by Zech et al. [15] 
was not analyzed. This should not have altered our 
results significantly since values obtained by ex- 
tended (multicompartmental) and by single- 
exponential analysis correlated well in nor- 
motriglyceridemic subjects [ 161. The weight reduc- 
tion in subjects 1 and 3 may have decreased the 
synthesis and concentrations of VLDL-TG in these 
two subjects but this should not affect FCR values 
[17,18]. 
The current results are in fact in accordance with 
many previous studies, indicating that the 
clearance of exogenous or endogenous fat was not 
impaired by administration of estrogen contai~ng 
drugs [19-231. On the other hand, under a variety 
of disease or experimental conditions suppression 
of HL activity has resulted in the accumulation of 
TG-rich lipoproteins in animals and man. Using a 
nonhuman primate model, Goldberg et al. [2] 
achieved complete inhibition of circulating HL ac- 
tivity and demonstrated that accumulation of 
VLDL, IDL and lesser density LDL in plasma oc- 
curred in association with an impaired conversion 
of radiolabeled VLDL to IDL and LDL. In some 
studies in the rat analogous results have been ob- 
tained [3,4], Familial hepatic lipase deficiency is 
also characterized by accumulation of TG-rich 
lipoprotein fractions in plasma [24]. 
It is possible to reconcile these seemingly con- 
tradictory results. The present study shows that 
moderate reductions in HL activity resembling 
those brought about by cyclic fluctuations in 
estrogen production in normal females [6] do not 
impair the removal efficiency of TG in the VLDL 
density class. This does not rule out the possibility 
that a certain ‘threshold’ level of HL activity is re- 
quired for the completion of the removal process. 
Thus, it is possible that hepatic lipase, although 
not a rate-limiting enzyme or even a major 
regulator in the catabolism of VLDL, is never- 
theless necessary for the functioning of the VLDL 
-+ IDL ---+ LDL pathway. Such a ‘permissive’ 
role of hepatic lipase would be in accordance with 
the findings that total or near-total inhibition of 
HL activity caused disturbances in the catabolism 
of TG-rich lipoproteins ]2-4,241, whereas 
moderate changes in the physiological range did 
not. It is not clear whether this postulated ‘per- 
missive’ effect of hepatic lipase is a direct effect on 
TG-rich lipoproteins, or an indirect effect caused 
by an impaired action on HDLZ. 
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